Evaluation of damage in giant cell arteritis

Rheumatology (United Kingdom)

Volumn 57, Issue 2, 2018, Pages 322-328

  Kermani, Tanaz A ^a   Sreih, Antoine G ^b   Cuthbertson, David ^c   Carette, Simon ^d   Hoffman, Gary S ^e   Khalidi, Nader A ^f   Koening, Curry L ^g   Langford, Carol A ^e   McAlear, Carol A ^b   Monach, Paul A ^h   Moreland, Larry ⁱ   Pagnoux, Christian ^d   Seo, Philip ^j   Warrington, Kenneth J ^k   Ytterberg, Steven R ^k   Merkel, Peter A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d MOUNT SINAI HOSPITAL   (Canada)

^e CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^f MCMASTER UNIVERSITY   (Canada)

^g UNIVERSITY OF UTAH   (United States)

^h BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k Mayo Clinic   (United States)

more..

Author keywords

Damage; Giant cell arteritis; Large artery manifestations; Large vessel vasculitis; Vasculitis

Indexed keywords

AGED; AORTIC ANEURYSM; ARTERY DISEASE; ARTERY OCCLUSION; ARTERY THROMBOSIS; ARTICLE; BLINDNESS; BODY WEIGHT GAIN; CARDIOVASCULAR DISEASE ASSESSMENT; CATARACT; CLAUDICATION; CONTROLLED STUDY; DIPLOPIA; DISEASE DURATION; EYE DISEASE; FEMALE; FOLLOW UP; GIANT CELL ARTERITIS; HUMAN; HYPERTENSION; ISCHEMIC OPTIC NEUROPATHY; LARGE VESSEL VASCULITIS INDEX OF DAMAGE; LIMB DISEASE; LONGITUDINAL STUDY; LOW VISION; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; OSTEOPOROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; VASCULAR DISEASE; VASCULITIS DAMAGE INDEX; VISUAL IMPAIRMENT; CLINICAL TRIAL; COMPLICATION; EVALUATION STUDY; INTERMITTENT CLAUDICATION; MIDDLE AGED; MULTICENTER STUDY; ODDS RATIO; PATHOLOGY; RECURRENT DISEASE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME FACTOR;

AGED; EYE DISEASES; FEMALE; FOLLOW-UP STUDIES; GIANT CELL ARTERITIS; HUMANS; INTERMITTENT CLAUDICATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 85041520199     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kex397     Document Type: Article

References (32)

1. Jennette JC, Falk RJ, Bacon PA et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1-11
2. Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008;372:234-45
3. Weyand CM, Goronzy JJ. Clinical practice. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med 2014;371:50-7
4. Ostberg G. Morphological changes in the large arteries in polymyalgia arteritica. Acta Med Scand Suppl 1972;533:135-59
5. Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum 1999;42:311-7
6. Blockmans D, de Ceuninck L, Vanderschueren S et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum 2006;55:131-7
7. Prieto-Gonzalez S, Arguis P, Garcia-Martinez A et al. Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. Ann Rheum Dis 2012;71:1170-6
8. Kermani TA, Warrington KJ, Crowson CS et al. Largevessel involvement in giant cell arteritis: a populationbased cohort study of the incidence-trends and prognosis. Ann Rheum Dis 2013;72:1989-94
9. Naderi N, Mohammad AJ, Turesson C. Large vessel involvement in biopsy-proven giant cell arteritis: incidence, distribution, and predictors. Scand J Rheumatol 2017;46:215-21
10. Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003;49:703-8
11. Chandran A, Udayakumar PD, Kermani TA et al. Glucocorticoid usage in giant cell arteritis over six decades (1950 to 2009). Clin Exp Rheumatol 2015;33(Suppl 89):98-102
12. Exley AR, Bacon PA, Luqmani RA et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371-80
13. Exley AR, Bacon PA, Luqmani RA et al. Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). Br J Rheumatol 1998;37:57-63
14. Aydin SZ, Direskeneli H, Sreih A et al. Update on outcome measure development for large vessel vasculitis: report from OMERACT 12. J Rheumatol 2015;42:2465-9
15. Hunder GG, Bloch DA, Michel BA et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122-8
16. Kamali S, Erer B, Artim-Esen B et al. Predictors of damage and survival in patients with Wegener's granulomatosis: analysis of 50 patients. J Rheumatol 2010;37:374-8
17. Seo P, Min YI, Holbrook JT et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 2005;52:2168-78
18. Seo P, Jayne D, Luqmani R, Merkel PA. Assessment of damage in vasculitis: expert ratings of damage. Rheumatology 2009;48:823-7
19. Liozon E, Roblot P, Paire D et al. Anticardiolipin antibody levels predict flares and relapses in patients with giant-cell (temporal) arteritis. A longitudinal study of 58 biopsyproven cases. Rheumatology 2000;39:1089-94
20. Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000;43:1041-8
21. Alba MA, Garcia-Martinez A, Prieto-Gonzalez S et al. Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine 2014;93:194-201
22. Kermani TA, Warrington KJ, Cuthbertson D et al. Disease relapses among patients with giant cell arteritis: a prospective, longitudinal cohort study. J Rheumatol 2015;42:1213-7
23. Suppiah R, Flossman O, Mukhtyar C et al. Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. Ann Rheum Dis 2011;70:80-5
24. Robson J, Doll H, Suppiah R et al. Damage in the ANCAassociated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis 2015;74:177-84
25. Mohammad AJ, Bakoush O, Sturfelt G, Segelmark M. The extent and pattern of organ damage in small vessel vasculitis measured by the Vasculitis Damage Index (VDI). Scand J Rheumatol 2009;38:268-75
26. Robson J, Doll H, Suppiah R et al. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology 2015;54:471-81
27. Exley AR, Carruthers DM, Luqmani RA et al. Damage occurs early in systemic vasculitis and is an index of outcome. QJM 1997;90:391-9
28. Koldingsnes W, Nossent H. Predictors of survival and organ damage in Wegener's granulomatosis. Rheumatology 2002;41:572-81
29. Miloslavsky EM, Naden RP, Bijlsma JW et al. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Ann Rheum Dis 2017;76:543-6
30. Schmidt WA, Moll A, Seifert A et al. Prognosis of largevessel giant cell arteritis. Rheumatology 2008;47:1406-8
31. Muratore F, Kermani TA, Crowson CS et al. Large-vessel giant cell arteritis: a cohort study. Rheumatology 2015;54:463-70
32. Prieto-Gonzalez S, Garcia-Martinez A, Arguis P, Cid MC. Early improvement of radiological signs of large-vessel inflammation in giant cell arteritis upon glucocorticoid treatment. Rheumatology 2013;52:1335-6